NextCell Pharma AB
About
NextCell Pharma is a Swedish clinical-stage biotechnology company developing allogeneic mesenchymal stromal cell therapies for immune-mediated diseases. Our lead program, NXTCL-T1D™, is being developed as a disease-modifying treatment for type 1 diabetes, with the aim of preserving endogenous insulin production through controlled immunomodulation. The proprietary NXTCL™ platform combines donor selection, scalable GMP manufacturing and cryopreserved off-the-shelf products designed for consistent potency and practical clinical use. NXTCL-T1D has been evaluated in clinical trials with long-term follow-up beyond five years. NextCell is advancing its clinical and regulatory strategy in Japan and seeking strategic collaborations for development and commercialization in Japan and broader Asia.
Business Domain / 分野
Business Type / 業種
Disease Area / 疾患領域
Modalities / モダリティ
Technologies / 技術
Additional Information
Researched company/organisation type / マッチングご希望企業・機関のタイプ
Researched disease area / マッチングご希望の疾患領域
Researched Modality / マッチングご希望のモダリティ
Researched Technologies / マッチングご希望の技術